These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25487958)

  • 1. The criteria of the Italian Federation of Thrombosis Centres on DOACs: a "real world" application in nonvalvular atrial fibrillation patients already on vitamin K antagonist.
    Barcellona D; Luzza M; Battino N; Fenu L; Marongiu F
    Intern Emerg Med; 2015 Mar; 10(2):157-63. PubMed ID: 25487958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Satisfaction, quality of life and perception of patients regarding burdens and benefits of vitamin K antagonists compared with direct oral anticoagulants in patients with nonvalvular atrial fibrillation.
    Contreras Muruaga MDM; Vivancos J; Reig G; González A; Cardona P; Ramírez-Moreno JM; Martí J; Suárez Fernández C;
    J Comp Eff Res; 2017 Jun; 6(4):303-312. PubMed ID: 28353372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with non-valvular atrial fibrillation on vitamin k antagonists or direct-acting oral anticoagulants: patients profile and long-term follow up outcomes.
    Sigismondi A; Camacho-Freire SJ; León-Jiménez J; Isasti-Aizpurva G; García-Lizana MD; Morgado-García de Polavieja JI; Caro-Fernández FJ; Roa-Garrido J; Navarro-Roldán F; Díaz-Fernández JF
    Arch Cardiol Mex; 2019; 89(4):382-392. PubMed ID: 31834326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of vitamin K antagonist oral anticoagulation in 322 patients with atrial fibrillation - real-life data from a survey in Eastern Switzerland.
    Maeder MT; König T; Bogdanovic S; Schneider I; Eugster W; Ammann P; König M; Beer J; Rickli H
    Swiss Med Wkly; 2017; 147():w14503. PubMed ID: 29039622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin K antagonists in patients with nonvalvular atrial fibrillation: appropriateness and quality of treatment in an Italian cohort.
    Pereira de Sousa L; Burba I; Ruperto C; Lattuada L; Barbone F; Di Chiara A
    J Cardiovasc Med (Hagerstown); 2013 Jul; 14(7):534-40. PubMed ID: 23328227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy.
    Zolfaghari S; Harenberg J; Froelich L; Wehling M; Weiss C
    Semin Thromb Hemost; 2014 Feb; 40(1):121-8. PubMed ID: 24381153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence to recommendations of the Therapeutic Positioning Report about treatment with oral anticoagulants in elderly patients with atrial fibrillation. The ESPARTA study.
    Suárez Fernández C; Mostaza JM; Castilla Guerra L; Cantero Hinojosa J; Suriñach JM; Acosta de Bilbao F; Tamarit JJ; Diaz Diaz JL; Hernandez JL; Cazorla D; Ràfols C;
    Med Clin (Barc); 2018 Jul; 151(1):8-15. PubMed ID: 28992980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life.
    Becattini C; Franco L; Beyer-Westendorf J; Masotti L; Nitti C; Vanni S; Manina G; Cattinelli S; Cappelli R; Sbrojavacca R; Pomero F; Marten S; Agnelli G
    Int J Cardiol; 2017 Jan; 227():261-266. PubMed ID: 27843050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis.
    De Gottardi A; Trebicka J; Klinger C; Plessier A; Seijo S; Terziroli B; Magenta L; Semela D; Buscarini E; Langlet P; Görtzen J; Puente A; Müllhaupt B; Navascuès C; Nery F; Deltenre P; Turon F; Engelmann C; Arya R; Caca K; Peck-Radosavljevic M; Leebeek FWG; Valla D; Garcia-Pagan JC;
    Liver Int; 2017 May; 37(5):694-699. PubMed ID: 27778440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A simple method to identify patients on long-term warfarin who may derive the most benefit from new oral anticoagulants.
    Carrier M; Kimpton M; Wells PS; Langlois N; Kherani S; Le Gal G
    Blood Coagul Fibrinolysis; 2014 Dec; 25(8):812-5. PubMed ID: 24914740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Satisfaction, quality of life and therapy adherence assessment in real life patients transitioning from vitamin K antagonists to direct oral anticoagulants.
    Serrao A; Lucani B; Assanto Manfredi G; Fiori L; Baldacci E; Aprile SM; Chistolini A
    J Thromb Thrombolysis; 2020 Oct; 50(3):718-723. PubMed ID: 32112201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of non-vitamin K antagonist oral anticoagulants in Primary Care: ACTUA study].
    Barrios V; Escobar C; Lobos JM; Polo J; Vargas D
    Semergen; 2017 Oct; 43(7):477-485. PubMed ID: 28029563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preference for direct oral anticoagulants in patients treated with vitamin K antagonists for venous thromboembolism.
    Brekelmans MP; Kappelhof M; Nieuwkerk PT; Nierman M; Buller HR; Coppens M
    Neth J Med; 2017 Mar; 75(2):50-55. PubMed ID: 28276323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation.
    Gallego P; Roldan V; Marín F; Romera M; Valdés M; Vicente V; Lip GY
    Thromb Haemost; 2013 Dec; 110(6):1189-98. PubMed ID: 24096615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation.
    Mostaza JM; Suarez C; Cepeda JM; Manzano L; Sánchez D;
    BMC Cardiovasc Disord; 2021 Aug; 21(1):384. PubMed ID: 34372782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term vitamin K antagonists treatment patterns of Non-Valvular Atrial Fibrillation (NVAF): a population-based cohort study.
    Renoux C; Coulombe J; Suissa S
    BMC Cardiovasc Disord; 2016 May; 16():84. PubMed ID: 27160254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Novel oral anticoagulants and atrial fibrillation in the elderly].
    Hanon O
    Geriatr Psychol Neuropsychiatr Vieil; 2013 Dec; 11(1 Suppl):34-40. PubMed ID: 24463062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Vitamin K antagonist, direct oral anticoagulants: Where is the truth?].
    Laroche JP; Schved JF
    J Mal Vasc; 2016 Dec; 41(6):383-388. PubMed ID: 27817997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Quality of life of elderly people on oral anticoagulant for atrial fibrillation: VKA versus direct oral anticoagulants].
    Fareau S; Baumstarck K; Farcet A; Molines C; Auquier P; Retornaz F
    Geriatr Psychol Neuropsychiatr Vieil; 2015 Mar; 13(1):45-54. PubMed ID: 25786423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.